CytoMed Therapeutics Limited
GDTC · NASDAQ
Market closed$1.00$-0.020000 (-1.96%)After hours $1.00 · 0.00%
Key statistics
Previous close$1.02
Open$1.00
Day high$1.00
Day low$0.990000
52-week high$3.68
52-week low$0.680000
Market cap11.83M
Volume9.21K
Average volume18.94K
P/E ratio-4.63
Forward P/E—
EPS-0.22
Dividend yield0.00%
Market context
Why it moved
GDTC experienced a modest decline today, likely driven by low trading volume and a lack of significant positive catalysts, resulting in light selling pressure that pushed the stock slightly below its previous close.
What is happening
Recent company-specific developments and publisher coverage.
Stock Titan · June 23, 2026CytoMed Therapeutics (NASDAQ: GDTC) chair ups exposure and funds LongevityBank R&DStock Titan · June 15, 2026CytoMed Therapeutics (NASDAQ: GDTC) director buys 112,000 shares in open marketGlobeNewswire · January 13, 2026CytoMed Therapeutics’ new year update and seeksGlobeNewswire · November 18, 2025CytoMed Therapeutics Completes Acquisition of T Cell Technology from UK to Treat Cancers in China and India Benzinga · January 28, 2026CytoMed Therapeutics Refutes Recent Statements Regarding Inaccurate, Misleading Claims About Company's Research Programs, Clinical Progress, And Operations Benzinga · December 9, 202512 Health Care Stocks Moving In Tuesday's Pre-Market Session Benzinga · December 8, 2025CytoMed Therapeutics Enters MoU With Universiti Malaya Medical Centre To Establish Phase 1 Clinical Trial Site To Investigate Safety And Efficacy Of CTM-GDT for No-Option Cancer Patients Benzinga · December 8, 2025CytoMed Therapeutics Enters Into MOU With UMMC To Establish Phase I Clinical Trial To Investigate Safety And Efficacy Of CytoMed's Patented Allogeneic Unmodified Gamma Delta T Cells For No-Option Cancer Patients In Malaysia Benzinga · August 28, 2025CytoMed Expands Clinical-Scale NK Cells From Decade-Old Cord Blood; Forms New Cord Blood-Derived Biotech Under LongevityBank To Drive Growth And Revenue Benzinga · August 19, 2025Reported Earlier, CytoMed Therapeutics Limited Announces At The Market Offering Program For Up To $4.3M In Ordinary Shares Through R.F. Lafferty & Co Inc